A phase Ib combination trial of PU-H71 in patients with metastatic pancreatic cancer

Trial Profile

A phase Ib combination trial of PU-H71 in patients with metastatic pancreatic cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs PU H71 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Samus Therapeutics
  • Most Recent Events

    • 06 Apr 2017 New trial record
    • 30 Mar 2017 According to a Samus Therapeutics media release, the US FDA has accepted an Investigative New Drug (IND) application to facilitate this trial for review. The company expects to treat the first patient in this trial in early second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top